Orforglipron
Stories
-
Eli Lilly launches Life Doesn't Slow Down campaign for Foundayo
The company announced a new campaign encouraging patients to discuss weight-loss options with doctors. The campaign highlights Foundayo, a GLP-1 pill approved by the FDA in April 2026, and features comedian Leanne Morgan as a spokesperson.
-
Eli Lilly posts results of Phase 3 orforglipron vs dapagliflozin study
The company posted results for the ACHIEVE-2 study, a Phase 3, randomized, open-label trial that enrolled 962 participants with type 2 diabetes. The study compared once-daily oral orforglipron (LY3502970) with dapagliflozin and completed primary data collection on September 26, 2025.
-
Results posted for phase 3 orforglipron study in type 2 diabetes
Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study enrolled 546 participants and completed primary data collection on September 15, 2025.